Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database
Compared to the adverse events reported in clinical trials and drug labels, no unreported signals were identified. This finding will provide clinicians with a more comprehensive understanding of the clinical application of zanubrutinib and provide valuable insights for future investigations.
Authors
- Yuanrong Yang (ORCID: https://orcid.org/0000-0002-1834-0973)
- Yajiao Huang
- Yan Chen (ORCID: https://orcid.org/0000-0001-8667-9023)
- Biao Zhang (ORCID: https://orcid.org/0000-0003-0577-4198)
- Xiaolu Chen (ORCID: https://orcid.org/0000-0002-5487-7882)
Institutions
- Yangtze University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1080/14740338.2025.2465872
- Citations
- 3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 4.88